Deep Phenotyping of Hearing Instability Disorders: Cohort Establishment, Biomarker Identification, Development of Novel Phenotyping Measures, and Discovery of Therapeutic Targets

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorNational Institute on Deafness and Other Communication Disorders (NIDCD)

About this trial

Background:

Disorders of hearing instability (HI) are poorly characterized and ineffectively treated. HI can cause fluctuations in hearing thresholds and speech understanding. Researchers want to use a specialized form of magnetic resonance imaging (MRI) and blood tests to learn more about HI.

Objective:

To characterize a cohort of people with HI and to correlate HI with other data, including hearing evaluations, as well as radiologic and immunologic biomarkers of inflammation over time.

Eligibility:

Adults ages 18-80 who have symptoms consistent with possible HI.

Design:

Participants will be screened with a medical and hearing history and medical record review.

Participants will have physical exams. Their head and neck will be examined. They will have blood drawn.

Participants will have hearing tests. They will wear headphones or foam earplugs. They will listen to different tones. They may describe what they hear.

Participants will have balance tests. They will wear goggles as they watch moving lights or while cold or warm air is blown into their ears. They will sit in a spinning chair in a quiet, dark booth. From a reclining position, they will raise their head while clicking sounds are played into their ears.

Participants will have MRIs of the inner ear and brain. The MRI scanner is a metal cylinder surrounded by a strong magnetic field. During the MRIs, participants will lie on a table that slides in and out of the scanner. Soft padding or a coil will be placed around their head. They will get a contrast agent through an intravenous catheter.

Participation will last up to 15 months.

...

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Provision of signed and dated informed consent.

Stated willingness to comply with all study procedures and availability for the duration of the study

All genders, aged 18-80 years

No air-bone gaps in excess of 10 dB for 500-4000 Hz indicative of conductive HL in at least 1 ear.

Disqualifiers

Presence of non-MRI compatible devices (cardiac pacemaker, meta<specific devices (e.g., cardiac pacemaker)

Pregnancy or lactation

Known allergic reactions to gadolinium

Febrile illness within 2 weeks that could affect immune profiling*

Trial population

This study will enroll up to a total of 150 patients with HI. The enrollment target is between 10-30 patients per clinical subtype for at least 2 clinical subtypes of HI (i.e., without or with EH, without or with significant immune cell, cytokine or FLAIR positivity). 20 cytokines/chemokines in patients with Meniere s disease that revealed statistically higher levels of IL-1Beta compared to healthy controls (Flook et al., 2019), a sample size of 40-50 patients would be required for 80% power to detect an immune subtype associated with IL-1Beta.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

210 Participants
are grouped into 1 trial group
Group A: 1/All Patients

Trial outcomes

Primary outcomes

1

Phenomic features

To identify phenotype features associated with hearing fluctuation

Time frame
Day 90, 180, 270, 360, and 450, respectively +/- 14 days

Secondary outcomes

1

Subdivisions of phenomic features

To Identify a variety of phenomic features of patients with HI that allow assignment to clinical subdivisions.

Time frame
Day 90, 180, 270, 360, and 450, respectively +/- 14 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.